{"url_path":"/sec/bntc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1808898/0001193125-26-222885-index.html","accession_number":"0001193125-26-222885","cik":"0001808898","ticker":"BNTC","issuer_name":"Benitec Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1808898/0001193125-26-222885-index.html","primary_entity_key":"0001808898","primary_entity_name":"Benitec Biopharma Inc."},"word_count":186,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nNumber\n\n \n\nDescription of Document\n\n \n\n \n\n \n\n31.1\n\n \n\n[Statement of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*](bntc-ex31_1.htm)\n\n \n\n \n\n \n\n31.2\n\n \n\n[Statement of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*](bntc-ex31_2.htm)\n\n \n\n \n\n \n\n32.1\n\n \n\n[Statement of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**](bntc-ex32_1.htm)\n\n \n\n \n\n \n\n32.2\n\n \n\n[Statement of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**](bntc-ex32_2.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n104\n\n \n\nCover page formatted as Inline XBRL and contained in Exhibit 101\n\n \n\n* Filed herewith.\n\n** Furnished, not filed.\n\n38\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nBenitec Biopharma Inc.\n\n \n\n \n\n \n\nDated: May 14, 2026\n\n \n\n/s/ Jerel Banks\n\n \n\n \n\nDr. Jerel Banks\n\n \n\n \n\nExecutive Chairman and Chief Executive Officer\n\n \n\n \n\n(principal executive officer)\n\n \n\n \n\n \n\n \n\n \n\n/s/ Megan Boston\n\n \n\n \n\nMegan Boston\n\n \n\n \n\nChief Financial Officer and Secretary (principal financial and accounting officer)\n\n \n\n39"}